PD-1单抗大适应证销售放量,君实生物业绩减亏三成

第一财经
30 Oct 2024

10月29日晚间,君实生物(01877.HK、688180.SH)发布的三季报显示,今年前三季度,公司归属上市公司股东的净亏损收窄至9.27亿元,相比去年同期减亏4.8亿元,即减亏34.12%。  业绩减亏背后,一是源于君实生物商业化药品销售收入的增长;二是公司也将资源聚焦于更具潜力的研发项目,临床、技术服务费及职工薪酬相应减少。  今年前三季度,君实生物实现营收12.71亿元,同比增长29%。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10